118 related articles for article (PubMed ID: 20581458)
1. Oncogenic c-kit transcript is a target for binase.
Mitkevich VA; Petrushanko IY; Kretova OV; Zelenikhin PV; Prassolov VS; Tchurikov NA; Ilinskaya ON; Makarov AA
Cell Cycle; 2010 Jul; 9(13):2674-8. PubMed ID: 20581458
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes.
Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA
Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339
[TBL] [Abstract][Full Text] [Related]
3. [Binase possesses a selective cytotoxic action on kit-transformed precursors of myeloid cells].
Petrushanko IIu; Zelenikhin PV; Mit'kevich VA; Kleĭmenova AA; Prasolov VS; Makarov AA; Il'inskaia ON
Biofizika; 2007; 52(5):876-81. PubMed ID: 17969922
[TBL] [Abstract][Full Text] [Related]
4. Binase cleaves cellular noncoding RNAs and affects coding mRNAs.
Mitkevich VA; Tchurikov NA; Zelenikhin PV; Petrushanko IY; Makarov AA; Ilinskaya ON
FEBS J; 2010 Jan; 277(1):186-96. PubMed ID: 19968715
[TBL] [Abstract][Full Text] [Related]
5. [Expression of FLT3-ITD oncogene confers mice progenitor B-cells BAF3 sensitivity to the ribonuclease binase cytotoxic action].
Mit'kevich VA; Orlova NN; Petrushanko IIu; Simonenko OV; Spirin PV; Prokofeva MM; Gornostaeva AS; Stocking C; Makarov AA; Prasolov VS
Mol Biol (Mosk); 2013; 47(2):282-5. PubMed ID: 23808162
[TBL] [Abstract][Full Text] [Related]
6. Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response.
Ilinskaya ON; Zelenikhin PV; Petrushanko IY; Mitkevich VA; Prassolov VS; Makarov AA
Biochem Biophys Res Commun; 2007 Oct; 361(4):1000-5. PubMed ID: 17689490
[TBL] [Abstract][Full Text] [Related]
7. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
8. [Combination of RNase Binase and AKT1/2 Kinase Inhibitor Blocks Two Alternative Survival Pathways in Kasumi-1 Cells].
Mitkevich VA; Petrushanko IY; Engelhardt MG; Kechko OI; Makarov AA
Mol Biol (Mosk); 2022; 56(5):764-773. PubMed ID: 36165015
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
[TBL] [Abstract][Full Text] [Related]
10. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
11. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
[TBL] [Abstract][Full Text] [Related]
14. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
16. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
Blom T; Fox H; Angers-Loustau A; Peltonen K; Kerosuo L; Wartiovaara K; Linja M; Jänne OA; Kovanen P; Haapasalo H; Nupponen NN
Int J Cancer; 2008 Aug; 123(4):793-800. PubMed ID: 18506689
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
18. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
19. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
[TBL] [Abstract][Full Text] [Related]
20. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
